ArticleCureus2025
Refractory Chronic Plaque Psoriasis and Psoriatic Arthritis Successfully Managed With Combined Secukinumab and Apremilast Therapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin condition with variable clinical courses and therapeutic responses. We present the case of a 55-year-old female with chronic plaque psoriasis refractory to multiple biologic agents, including conventional systemic immunosuppressants, Janus kinase inhibitors, and interleukin inhibitors. Despite sequential biologic regimens, the patient demonstrated only partial and transient improvement. Given the persistence of severe disease, combination therapy with secukinumab, an IL-17A inhibitor, and apremilast, a phosphodiesterase-4 inhibitor, was initiated. This dual approach resulted in significant clinical improvement and eventual disease resolution, with sustained remission over follow-up. The case highlights the potential role of combination targeted therapy in managing biologic-refractory psoriasis and emphasizes the need for individualized treatment strategies in complex or resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.